science

Targeted intra-operative radiotherapy

Targeted intra-operative radiotherapy is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Targeted intra-operative radiotherapy rather than just read about it. In short: Targeted intra-operative radiotherapy, also known as targeted IORT, is a technique of giving radiotherapy to the tissues surrounding a cancer after its surgical removal, a form of intraoperative radiation therapy. The technique was designed in 1998 at the University College London.

Key takeaways

Targeted intra-operative radiotherapy belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Targeted intra-operative radiotherapy to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Targeted intra-operative radiotherapy from memory before moving on to harder problems.

Reference excerpt

Targeted intra-operative radiotherapy, also known as targeted IORT, is a technique of giving radiotherapy to the tissues surrounding a cancer after its surgical removal, a form of intraoperative radiation therapy. The technique was designed in 1998 at the University College London. One IORT technique is known as TARGIT (TARGeted Intraoperative radioTherapy). TARGIT is a method where the radiation is applied during an operation and targeted to the peri-tumoural tissues. TARGIT technique was designed at University College London by Jayant S. Vaidya (who coined the TARGIT acronym) and Michael Baum along with Jeffrey S. Tobias in 1998. The term was first used when the technique was described.

Medical uses

Breast cancer The largest experience with IORT using the TARGIT technique and the best evidence for its potentials exists in breast cancer where a substantial number of patients have already been treated. In patients having lumpectomy for breast cancer, the TARGIT-A(lone) randomized controlled trial (recruitment from 2000–2012) tested whether TARGIT within a risk-adapted approach is non-inferior to conventional course of external beam postoperative radiotherapy given over several weeks.

Adoption On 25 July 2014 the UK National Institute for Health and Care Excellence (NICE) gave provisional recommendation for the use of TARGIT IORT with Intrabeam in the UK National Health Service. In September 2014, NICE requested further information from the clinical trial investigators, citing several comments and concerns. Concerns cited included the immaturity of the data with a median follow up of the entire population being only two years and five months, as well as the noninferiority criterion used in the study. This extra information was supplied by the authors, and has since been published as part of the comprehensive paper on TARGIT-A trial. In 2017, NICE described it as an option for early breast cancer. The 2015 update of guidelines of the Association of Gynaecological Oncology (AGO) (an autonomous community of the German Society of Gynaecology and Obstetrics (DGGG) and the German Cancer Society) includes TARGIT IORT during lumpectomy as a recommended option for women with a T1, Grade 1 or 2, ER positive breast cancer. On 21 May 2015, the Australian Government Medical Services Advisory Committee (MSAC) announced that "After considering the available evidence in relation to safety, clinical effectiveness and cost-effectiveness, MSAC supported public funding of a new Medicare Benefits Schedule (MBS) item for treatment of pathologically documented invasive ductal breast cancer in eligible patients with TARGIT-IORT when used concurrently with breast-conserving surgery". The Australian Government also approved budget item for the treatment of early stage breast cancer using targeted intraoperative radiotherapy and patients can avail of this treatment from 1 September 2015. On 26 May 2015, in response to a query by the British Medical Journal, NICE clarified that while their appraisal is going on, TARGIT IORT with Intrabeam can continue to be offered to patients who need it. About 260 centres in over 35 countries including North America (about 80 centres), South America, Europe (e.g., 60 centres in Germany), Australia, Middle East (e.g., 9 centres in Israel), and the Far East are currently using TARGIT IORT for breast cancer treatment, and over 45,000 patients have so far been treated using TARGIT IORT. Evaluation of the long-term outcomes from an open-label randomised controlled trial (TARGIT-A) published in 2020, demonstrated that TARGIT-IORT is as effective as whole breast external beam radiotherapy in controlling cancer for patients with breast cancer. The results also suggested deaths from other causes such as cardiovascular or lung problems or from other cancers were reduced over a 12-year follow up. A systematic review of partial breast irradiation (PBI) techniques (including TARGIT) versus whole breast radiotherapy, by Cochrane, found current evidence shows PBI provides slightly worse cancer control. A meta-analysis by authors of the TRAGIT-A trial found that PBI reduced non-breast cancer and overall mortality compared with whole breast radiation.

Rationale When breast cancer is surgically excised, it can come back (local recurrence) in the remaining breast or on the chest wall in a small proportion of women. Adjuvant radiotherapy is necessary if breast cancer is treated by removing only the cancerous lump with a rim of surrounding normal tissue, as it reduces the chance of local recurrence. When cancer does come back, it most commonly occurs in the tissues surrounding the original cancer (the tumour bed), even though there are multicentric cancers in remote areas of the breast. This suggests that it is most important to treat the tumour bed. The rationale for TARGIT is to deliver a high dose of radiation precisely to the tumour bed. Conventional radiation techniques such as external beam radiotherapy (EBRT) following surgical removal of the tumour have been time tested and proven to be effective. EBRT is usually given as a course of whole breast radiotherapy and an additional tumour bed boost, or partial breast irradiation of a smaller area. However, it has a few drawbacks; for example, the tumour bed where the boost dose should be applied can be missed due to the difficulties in localization of the complex wound cavity ("geographical miss"), even when modern radiotherapy planning is used. Additionally, the usual delay between the surgical removal of the tumour and EBRT may allow a repopulation of the tumour cells ("temporal miss"). These potentially harmful effects may be avoided by delivering the radiation more precisely to the targeted tissues leading to immediate sterilization of residual tumour cells. The use in TARGIT of a small treatment device which can be positioned in close physical proximity to the treatment site aims to avoid some of these practical issues. TARGIT irradiation has also been shown to affect the properties of wound fluid, which may be linked to cancer cell proliferation and possibly local recurrence. Based on results from the TARGIT-A trial it has been hypothesised that TARGIT may have an abscopal effect reducing the risk of non-cancer death, although this is not proven.

… excerpt ends here. Continue reading the full article.

Worked examples

Example 1 — a first encounter with Targeted intra-operative radiotherapy

Start with the simplest possible case. Write down what Targeted intra-operative radiotherapy claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Targeted intra-operative radiotherapy before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Targeted intra-operative radiotherapy ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Targeted intra-operative radiotherapy

In research: Targeted intra-operative radiotherapy appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Targeted intra-operative radiotherapy in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Targeted intra-operative radiotherapy is common in secondary-school and first-year university syllabi. It links to neighbouring topics Breast cancer, Radiation therapy procedures, Surgery, so understanding it makes those chapters shorter.
In everyday life: Look for Targeted intra-operative radiotherapy outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Targeted intra-operative radiotherapy” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Targeted intra-operative radiotherapy in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Targeted intra-operative radiotherapy means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Targeted intra-operative radiotherapy out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Targeted intra-operative radiotherapy in simple terms?

Why does Targeted intra-operative radiotherapy matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Targeted intra-operative radiotherapy?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Targeted intra-operative radiotherapy.